Navigation Links
Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
Date:1/30/2013

WORCESTER, Mass. and TORONTO, Jan. 30, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an overview on the early breast cancer competitive status of the lead cancer immunotherapy product, AE37, under development at its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).  A detailed update on development plans will be provided during the previously announced conference call scheduled for Thursday, January 31, 2013.  Antigen Express is in late Phase IIb clinical development for early stage breast cancer that has provided very encouraging interim results and Phase I testing in prostate cancer has been completed.

The specific advantage of the cancer immunotherapy product AE37 is in early breast cancer by potentially stimulating the immune system to target HER2 (the target for Herceptin's effect) on breast cancer cells at low levels independent of immune type of the person. This follows in the footsteps of one of the most successful therapeutics ever developed for breast cancer (Herceptin), though AE37 potentially addresses an early breast cancer patient population of unmet need several times more common than those treated with Herceptin. In particular, while Herceptin is approved for use in roughly 25% of early stage breast cancer patients with high expression of HER2, it is not approved for the larger group of women (50% of women with early breast cancer) who have lower levels of expression of the target for Herceptin (HER2). Rather than attacking HER2 cancer cells directly as does Herceptin, AE37 works by stimulating the immune system to recognize HER2. The greater sensitivity of the immune system can thereby be brought to bear to recognize and kill cancer cells in this larger low HER2 expressing early breast cancer population. An additional pot
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
10. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
11. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Taiwan,s GNT ... in Taipei on  August 25 ... platform, a targeted drug delivery technology that uses nano-scale ... was part of a joint press conference held by ... (GNT), showcasing GNT,s latest edible gold-based food and beverage ...
(Date:9/1/2015)... 1, 2015 Sargas Pharmaceutical Adherence and ... Drug Adherence m Health applications along with 24 ... of non face-to-face monitoring of twenty minutes per ... of our apps, doctors are now well prepared ... our ONCHIT certified Physician, Pharmacy and Patient portals ...
(Date:9/1/2015)... Agena Bioscience TM today announced the establishment ... commercial and financial hub from which many biotech and life ... in mainland China . "The ... sales with almost sixty MassARRAY ® Systems installed to ... allow us to expand our reach and foster a high ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:9/1/2015)... UK (PRWEB) , ... September 01, 2015 , ... ... a vacuum that creates negative pressure inside a wound to remove exudates, fluid, ... for treatment devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... it is now offering the MonaLisa Touch® , an innovative vaginal health ... MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition that ...
(Date:9/1/2015)... , ... September 01, 2015 ... ... Background Screeners (NAPBS®) has announced that Edge Information Management has been ... the Background Screening Credentialing Council (BSCC). , “Achieving and maintaining this ...
(Date:9/1/2015)... ... 2015 , ... PetPace, the provider of an innovative IoT ... today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Management Software packages in the US. Practice Management Software helps veterinarians manage every ...
(Date:9/1/2015)... ... September 01, 2015 , ... Discovia, ... entities, announced today that it has hired Scott Sanderson, an experienced business development ... capacity, Sanderson will be responsible for establishing and managing new client relationships in ...
Breaking Medicine News(10 mins):Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2
... interventions in future, study finds , , TUESDAY, April 7 ... two years after a diagnosis of early bladder cancer ... finds. , Researchers analyzed data on 20,713 Medicare patients ... The average cost of care for patients who received ...
... and possession of alcohol, zero tolerance prevent more than ... 7 (HealthDay News) -- Not all laws are created ... drinking-related auto accidents, say researchers who analyzed the impact ... Most effective, they found, are laws targeting the purchase ...
... scans improves access for patients to needed cancer ... GE Healthcare, a global leader in healthcare technology, ... the Centers for Medicare and Medicaid Services (CMS), ... tomography (PET) for Medicare beneficiaries who are diagnosed ...
... research exploring weight discrimination against women in the workplace. , ... , , , ... , , , ... , , , , ...
... offers helpATLANTA, April 7 Struggling with infertility issues ... a reality for some today. The troubled economy has ... shut down. And both women and men have biological ... have a baby but know they need some physical ...
... of a long-secret report by International Committee of the Red Cross ... secret detention centers committed gross violations of medical ethics and in ... ... (Vocus) April 7, 2009 -- The full disclosure of a ...
Cached Medicine News:Health News:Intensive Early Treatment Doesn't Help Bladder Cancer Survival 2Health News:Tough Legislation on Underage Drinking Seems to Save Lives 2Health News:Tough Legislation on Underage Drinking Seems to Save Lives 3Health News:GE Healthcare Applauds CMS for Supporting National FDG-PET Coverage Decision 2Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 2Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 3Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 4Health News:Infertility Issues and No Insurance Do Not Necessarily Mean No Hope for Baby 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 3
...
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: